Evaluate and care for patients with COVID‐19 for liver disease  Prioritize for COVID‐19 testing: (1) patients with cirrhosis, (2) patients with CLD receiving immunosuppressive medications, and (3) patients with new‐onset encephalopathy or other acute decompensation
Regularly monitor liver biochemistries
Consider non‐COVID‐19 etiologies for liver disease: (1) exacerbation of preexisting CLD or (2) drug‐induced hepatotoxicity
Use acetaminophen 2 g/day as preferred medication
Use nonsteroidal anti‐inflammatory drugs as needed
Consult the University of Liverpool document to assess possible drug interactions  Follow WHO guidelines for COVID‐19 diagnosis
Consider NAFLD as a prognostic factor for severe COVID‐19
Screen patients for hepatitis B surface antigen
Consider HBV prophylaxis prior to use of anti‐IL‐6, other immunosuppressive therapy
Monitor liver function tests of patients with CLD
Be alert to possible drug hepatotoxicity
Decompensated CLD and ALT >5 times ULD contraindications for remdesivir therapy
Prioritize persons with CLD for clinical trials  Test for COVID‐19 patients with acute decompensation or acute‐on‐chronic liver and per institution’s practices
Persons with NAFLD likely to have comorbidity risk factors for severe COVID‐19
Consider patients with CLD/COVID‐19 for early admission and clinical trial
Use acetaminophen (2–3 g/day is generally safe)
Limit use of nonsteroidal anti‐inflammatory drugs
Test for COVID‐19 patients with acute decompensation or acute‐on‐chronic liver and per institution’s practices
Persons with NAFLD likely to have comorbidity risk factors for severe COVID‐19
Consider patients with CLD/COVID‐19 for early admission and clinical trial
Use acetaminophen (2–3 g/day is generally safe)
Limit use of nonsteroidal anti‐inflammatory drugs